These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25824241)

  • 1. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells.
    Wang S; Mou Z; Ma Y; Li J; Li J; Ji X; Wu K; Li L; Lu W; Zhou T
    Biochem Pharmacol; 2015 May; 95(2):98-109. PubMed ID: 25824241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft.
    Ma YH; Wang SY; Ren YP; Li J; Guo TJ; Lu W; Zhou TY
    Acta Pharmacol Sin; 2019 Feb; 40(2):243-256. PubMed ID: 29773888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells.
    Xu L; Zhang L; Hu C; Liang S; Fei X; Yan N; Zhang Y; Zhang F
    Int J Oncol; 2016 Mar; 48(3):1175-86. PubMed ID: 26781188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells(BCSCs) by down-regulating the expression of Cyclin D1.
    Ma X; Zhang Y; Kang Y; Li L; Zheng W
    Biomed Pharmacother; 2016 Dec; 84():373-381. PubMed ID: 27668537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation.
    Su H; Xue Z; Feng Y; Xie Y; Deng B; Yao Y; Tian X; An Q; Yang L; Yao Q; Xue J; Chen G; Hao C; Zhou T
    Toxicol Appl Pharmacol; 2019 Dec; 384():114789. PubMed ID: 31669811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
    Ping SY; Wu CL; Yu DS
    Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Pharmacokinetic/Pharmacodynamic Model of Sunitinib and Dopamine in MCF-7/Adr Xenografts: Linking Cellular Heterogeneity to Tumour Burden.
    Wang S; Zhu X; Han M; Hao F; Lu W; Zhou T
    AAPS J; 2020 Feb; 22(2):45. PubMed ID: 32043246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer.
    Li J; Yao QY; Xue JS; Wang LJ; Yuan Y; Tian XY; Su H; Wang SY; Chen WJ; Lu W; Zhou TY
    Acta Pharmacol Sin; 2017 Sep; 38(9):1282-1296. PubMed ID: 28649130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
    Wu CL; Ping SY; Yu CP; Yu DS
    Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.
    Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
    Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
    Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
    Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
    Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
    J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salinomycin exerts anticancer effects on human breast carcinoma MCF-7 cancer stem cells via modulation of Hedgehog signaling.
    Lu Y; Ma W; Mao J; Yu X; Hou Z; Fan S; Song B; Wang H; Li J; Kang L; Liu P; Liu Q; Li L
    Chem Biol Interact; 2015 Feb; 228():100-7. PubMed ID: 25499043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cancer stem cells in breast cancer: potential anticancer properties of 6-shogaol and pterostilbene.
    Wu CH; Hong BH; Ho CT; Yen GC
    J Agric Food Chem; 2015 Mar; 63(9):2432-41. PubMed ID: 25686711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway.
    An H; Kim JY; Lee N; Cho Y; Oh E; Seo JH
    Biochem Biophys Res Commun; 2015 Oct; 466(4):696-703. PubMed ID: 26407842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin.
    Saha S; Mukherjee S; Mazumdar M; Manna A; Khan P; Adhikary A; Kajal K; Jana D; Sa G; Mukherjee S; Sarkar DK; Das T
    Transl Res; 2015 May; 165(5):558-77. PubMed ID: 25468484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
    French R; Hayward O; Jones S; Yang W; Clarkson R
    Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
    Takeuchi A; Eto M; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Itsumi M; Naito S
    Int J Oncol; 2012 May; 40(5):1691-6. PubMed ID: 22344606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.
    Yun EJ; Zhou J; Lin CJ; Hernandez E; Fazli L; Gleave M; Hsieh JT
    Clin Cancer Res; 2016 Feb; 22(3):670-9. PubMed ID: 26490309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
    Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
    J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.